Genetic screening could identify risk of advanced prostate cancer
New research from the Institute of Cancer Research in the UK suggests that screening men with a family history of prostate cancer for certain gene mutations could identify those who are at increased risk of aggressive forms of the disease and need lifelong monitoring.
Data shows Prolaris test predicts metastases in prostate cancer from biopsies
Myriad Genetics, Inc. has announced it has published data in the Journal of Urology demonstrating that its Prolaris test accurately predicted, based on biopsy specimens, which men would develop biochemical recurrence (BCR) or metastatic disease following radical prostate surgery.
Proton therapy for prostate cancer results in long-term patient survival and excellent quality of life
Five years after having proton therapy for early- and intermediate-risk prostate cancer, 99 percent of men are living cancer-free and with excellent quality of life, according to a University of Florida Proton Therapy Institute study. Three-quarters of those with high-risk prostate cancer are also disease-free.
Prostate cancer advance could improve treatment options
Researchers at the University of East Anglia have made an important advance in understanding genetic changes associated with terminal prostate cancer.Findings published today in the British Journal of Cancer, and funded by the Association for International Cancer Research (AICR), show how a genetic mutation in untreated patients is linked to aggressive cancer later in life.
Key cellular pathway identified in prostate cancer
Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor - the cellular component that binds to male hormones.
3D mapping biopsy found pockets of prostate cancer previous technique had missed
Ultrasound-guided biopsies miss prostate cancers that are detected by the slightly more expensive and slightly more invasive 3D mapping biopsies.
Researchers advance findings on key gene related to cancer metastasis
New evidence reported by researchers at Roswell Park Cancer Institute (RPCI) lends support to the hypothesis that the SSeCKS/AKAP12 gene is a key inhibitor of prostate cancer metastasis.
Factors produced in inflammatory cells may reawaken dormant prostate cancer cells
Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute discovered in pre-clinical models that dormant prostate cancer cells found in bone tissue can be reawakened, causing metastasis to other parts of the body. Understanding this mechanism of action may allow researchers to intervene prior to disease progression.
Radiotherapy plus hormone therapy cuts prostate cancer death in half, shows long-term study
Combination treatment more than halves mortality rates for prostate cancer, reports Norwegian health journal Dagens Medisin.The figures were presented by Norwegian cancer researcher Sophie Fosså at an international conference sponsored by the American Society of Clinical Oncology (ASCO) in San Francisco this week.
Targeting 'sleeper agent' cells in bones of prostate cancer patients
Dormant prostate cancer cells in bone tissue can be reawakened to cause secondary tumours, according to new research published in Endocrine-Related Cancer. Targeting the wake-up call could prevent metastasis and improve prostate cancer survival rates.